Harrow (Harrow) Retained Earnings : $-133.9 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Harrow Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Harrow's retained earnings for the quarter that ended in Dec. 2023 was $-133.9 Mil.

Harrow's quarterly retained earnings declined from Jun. 2023 ($-120.4 Mil) to Sep. 2023 ($-124.8 Mil) and declined from Sep. 2023 ($-124.8 Mil) to Dec. 2023 ($-133.9 Mil).

Harrow's annual retained earnings declined from Dec. 2021 ($-95.4 Mil) to Dec. 2022 ($-109.5 Mil) and declined from Dec. 2022 ($-109.5 Mil) to Dec. 2023 ($-133.9 Mil).

Harrow Retained Earnings Historical Data

The historical data trend for Harrow's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Retained Earnings Chart

Harrow Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-74.04

-77.40

-95.41

-109.49

-133.90

Harrow Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-109.49	-116.14	-120.37	-124.76	-133.90

Harrow Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Harrow (NAS:HROW) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Harrow (Harrow) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205

Website

https://www.harrow.com

Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.

Executives

Mark L Baum	director, 10 percent owner, officer: Chief Executive Officer	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence	director	354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll	officer: VP, Accounting and Reporting	437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks	director	40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer	director, 10 percent owner, officer: Chairman of the Board	1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc	other: Institutional Investor	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	other: Managing Mbr of Longboard Cap.	1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards	officer: Chief Operating Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi	director	2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni	10 percent owner	1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek	officer: Chief Commercial Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130